Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 1/2014

01-03-2014 | Original Research

Delta-catenin promotes the proliferation and invasion of colorectal cancer cells by binding to E-cadherin in a competitive manner with p120 catenin

Authors: Hong Zhang, Shun-Dong Dai, Di Zhang, Dong Liu, Fang-Yuan Zhang, Tian-Yi Zheng, Ming-Ming Cui, Chao-Liu Dai

Published in: Targeted Oncology | Issue 1/2014

Login to get access

Abstract

δ-Catenin is the only member of the p120 catenin (p120ctn) subfamily whose normal pattern of expression is restricted to the brain. Similar to p120ctn, δ-catenin can bind to the juxtamembrane domain of E-cadherin. We examined the expression of δ-catenin, p120ctn, and E-cadherin using immunohistochemistry in 95 cases of colorectal cancer (CRC) and 15 normal colon tissues. Co-immunoprecipitation was used to examine whether δ-catenin competed with p120ctn to bind E-cadherin in CRC cells. The effects of δ-catenin overexpression or siRNA-mediated knockdown on the proliferation and invasive ability of CRC cells were investigated using the MTT and Matrigel invasion assays. The results showed that positive δ-catenin expression was significantly more frequent in CRC compared to normal colon tissues and associated with poor differentiation, stage III–IV disease, and lymph node metastasis in CRC (all P < 0.05). In two CRC cell lines, δ-catenin bound to E-cadherin in competition with p120ctn. Overexpression of δ-catenin promoted the proliferation and invasion of CRC cells; knockdown of δ-catenin reduced CRC cell proliferation and invasion. In conclusion, we speculate that overexpression of δ-catenin reduces the expression of E-cadherin and alters the balance between E-cadherin and p120ctn, which in turn affects the formation of intercellular adhesions and promotes invasion and metastasis in CRC.
Appendix
Available only for authorised users
Literature
1.
2.
Nollet F, Berx G, van Roy F (1999) The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun 2(2):77–85PubMedCrossRef
3.
Iozzo RV, Zoeller JJ, Nystrom A (2009) Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol Cells 27(5):503–513PubMedCrossRef
4.
Shun CT, Wu MS, Lin JT et al (1998) An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer. Hepatogastroenterology 45(22):944–949PubMed
5.
St Croix B, Sheehan C, Rak JW et al (1998) E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 142(2):557–571PubMedCentralPubMedCrossRef
6.
Aberle H, Butz S, Stappert J et al (1994) Assembly of the cadherin–catenin complex in vitro with recombinant proteins. J Cell Sci 107(Pt 12):3655–3663PubMed
7.
Lu Q, Paredes M, Medina M et al (1999) Delta-catenin, an adhesive junction-associated protein which promotes cell scattering. J Cell Biol 144(3):519–532PubMedCentralPubMedCrossRef
8.
Thoreson MA, Anastasiadis PZ, Daniel JM et al (2000) Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. J Cell Biol 148(1):189–202PubMedCentralPubMedCrossRef
9.
10.
Thoreson MA, Reynolds AB (2002) Altered expression of the catenin p120 in human cancer: implications for tumor progression. Differentiation 70(9–10):583–589PubMedCrossRef
11.
Anastasiadis PZ, Reynolds AB (2000) The p120 catenin family: complex roles in adhesion, signaling and cancer. J Cell Sci 113(Pt 8):1319–1334PubMed
12.
Zhou J, Liyanage U, Medina M et al (1997) Presenilin 1 interaction in the brain with a novel member of the Armadillo family. Neuroreport 8(8):2085–2090PubMedCrossRef
13.
Ho C, Zhou J, Medina M et al (2000) Delta-catenin is a nervous system-specific adherens junction protein which undergoes dynamic relocalization during development. J Comp Neurol 420(2):261–276PubMedCrossRef
14.
Burger MJ, Tebay MA, Keith PA et al (2002) Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 100(2):228–237PubMedCrossRef
15.
Lu Q, Dobbs LJ, Gregory CW et al (2005) Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum Pathol 36(10):1037–1048PubMedCrossRef
16.
Zhang JY, Wang Y, Zhang D et al (2010) delta-Catenin promotes malignant phenotype of non-small cell lung cancer by non-competitive binding to E-cadherin with p120ctn in cytoplasm. J Pathol 222(1):76–88PubMed
17.
Yang I, Chang O, Lu Q et al (2010) Delta-catenin affects the localization and stability of p120-catenin by competitively interacting with E-cadherin. Mol Cells 29(3):233–237PubMedCentralPubMedCrossRef
18.
Gofuku J, Shiozaki H, Tsujinaka T et al (1999) Expression of E-cadherin and alpha-catenin in patients with colorectal carcinoma. Correlation with cancer invasion and metastasis. Am J Clin Pathol 111(1):29–37PubMed
19.
Ikeguchi M, Makino M, Kaibara N (2001) Clinical significance of E-cadherin–catenin complex expression in metastatic foci of colorectal carcinoma. J Surg Oncol 77(3):201–207PubMedCrossRef
20.
Daniel JM, Reynolds AB (1999) The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor. Mol Cell Biol 19(5):3614–3623PubMedCentralPubMed
21.
Chartier NT, Oddou CI, Laine MG et al (2007) Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer. Cancer Res 67(20):9781–9790PubMedCentralPubMedCrossRef
22.
Waltzer L, Bienz M (1999) The control of beta-catenin and TCF during embryonic development and cancer. Cancer Metastasis Rev 18(2):231–246PubMedCrossRef
23.
Zeng Y, Abdallah A, Lu JP et al (2009) delta-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles. Mol Cancer 8:19PubMedCentralPubMedCrossRef
24.
Dai SD, Wang Y, Zhang JY et al (2011) Upregulation of delta-catenin is associated with poor prognosis and enhances transcriptional activity through Kaiso in non-small-cell lung cancer. Cancer Sci 102(1):95–103PubMedCrossRef
Metadata
Title
Delta-catenin promotes the proliferation and invasion of colorectal cancer cells by binding to E-cadherin in a competitive manner with p120 catenin
Authors
Hong Zhang
Shun-Dong Dai
Di Zhang
Dong Liu
Fang-Yuan Zhang
Tian-Yi Zheng
Ming-Ming Cui
Chao-Liu Dai
Publication date
01-03-2014
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 1/2014
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-013-0269-6

Other articles of this Issue 1/2014

Targeted Oncology 1/2014 Go to the issue

Original Research

EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer

Original Research

Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

Review

Trends in cancer-targeted antibody–drug conjugates

Day-to-Day Practice

Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature

Adis Drug Evaluation

Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer

Review

Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits